Abstracts tagged "Diagnostic Tests"

Abstract Number: 1916 • 2015 ACR/ARHP Annual Meeting
Validation of Novel Biomarker Candidates for Systemic Sclerosis
Johannes Schulte-Pelkum¹, Petra Budde¹, Hans-Dieter Zucht¹, Daniel Wirtz¹, Peter Schulz-Knappe¹, Oliver Distler², Suzana Jordan³, Nicolas Hunzelmann⁴, Matthias Schneider⁵ and Britta Maurer², ¹Protagen AG, Dortmund, Germany, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Dermatology, University of Cologne, Cologne, Germany, ⁵Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease that manifests as progressive fibrosis of the skin and internal organs. SSc is associated with the…
Abstract Number: 2065 • 2015 ACR/ARHP Annual Meeting
Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Vinod Chandran¹, Daniela Cretu^2,3, Lisa Gao⁴, Kun Liang⁴, Antoninus Soosaipillai³ and Eleftherios Diamandis^2,3,5, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ³Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients. Therefore identifying soluble biomarkers for PsA will help in screening psoriasis…
Abstract Number: 2190 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratory Validation Exercise: Comparison of Enzyme-Linked Immunosorbant Assay (ELISA) and Chemiluminescence Immunoassay (CIA)
Maria Laura Bertolaccini¹, Danieli Andrade², Gabriella Lakos³, Rohan Willis⁴, Vittorio Pengo⁵, Alessandra Banzato⁶, Hannah Cohen⁷, Steven Krilis⁸, Doruk Erkan⁹ and on behalf of APS ACTION, ¹Lupus Unit, Rayne Institute, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³INOVA Diagnostics, Inc., San Diego, CA, ⁴Department of Internal Medicine, Antiphospholipid Standardization Laboratory, Division of Rheumatology, Galveston, TX, ⁵Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ⁶Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁷Hematology., University College London, LOndon, United Kingdom, ⁸Immunology, Allergy, and Infectious Diseases, St George Hospital, Kogarah NSW, Australia, ⁹Rheumatology, Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of disease over 10 years in persistently aPL-positive patients with/without…
Abstract Number: 2231 • 2015 ACR/ARHP Annual Meeting
Vitamin D Deficiency States Can be Actively Prevented. Results from a Cross-Sectional Study of over 3000 Patients with Rheumatic Diseases
Elena Nikiphorou¹, Pekka Hannonen¹, Paula Väre¹, Arto Kokko², Tuomas Rannio^3,4 and Tuulikki Sokka-Isler⁴, ¹Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Kuopio University Hospital, Kuopio, Finland, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Vitamin D (D25) deficiency has been an ongoing matter of concern, especially in countries at northern latitudes. The effects of D25 deficiency in patients…
Abstract Number: 2598 • 2015 ACR/ARHP Annual Meeting
Neutrophil Extracellular Trap Levels Measured By Cell Free Nucleosome ELISA in Serum Are Highly Specific and Sensitive for Rheumatoid Arthritis
Paul Hasler¹, Stavros Giaglis¹, Ulrich A. Walker², Erik Deman¹, Christoph Hemmeler¹, Christina Ryser¹, Samuel Kretzschmar¹, Guenther Schaefer³, Juliane Franz¹ and Sinuhe Hahn⁴, ¹Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ²Rheumatology, University Hospital, Basel, Basel, Switzerland, ³Dept. of Biomedicine, Laboratory of Prenatal Medicine, University Hospital Basel, Basel, Switzerland, ⁴Dept. of Biomedicine, Laboratory for Prenatal Medicine, University Hospital Basel, Basel, Switzerland
Background/Purpose: Rheumatoid factor (RF) or anti-citrullinated peptide antibody (ACPA) detection have limited clinical utility for the diagnosis of rheumatoid arthritis (RA), as the specificity and…
Abstract Number: 2614 • 2015 ACR/ARHP Annual Meeting
Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis
Lance Feller¹, Paul Tuttle IV², Austin M. Dalrymple³, Srikanth Bathula⁴, Katherine Temprano⁵, Reema H. Syed⁶, Rama Bandlamudi⁷, Kathryn Coulson⁸, Peri Pepmueller⁹ and Terry Moore¹⁰, ¹Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO, ²Saint Louis University, Saint Louis, MO, ³Pediatric Rheumatology, St. Louis University, St. Louis, MO, ⁴Rheumatology, Saint Louis University, Saint Louis, MO, ⁵Medicine/Rheumatology, Saint Louis University, St. Louis, MO, ⁶IM-Rheumatology, Saint Louis University, St. Louis, MO, ⁷Internal Medicine/Rheumatology, St. Louis Univ Health Sciences, St. Louis, MO, ⁸Rheumatology/ 213A, St. Louis University, St. Louis, MO, ⁹Rheumatology, Saint Louis University, St. Louis, MO, ¹⁰Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 101 • 2015 ACR/ARHP Annual Meeting
New Technologies for Typing Self-Identifying Antigens Encoded By HLA Genes Provide Cost-Effective Alternatives to Identifying B27 Allele Status in Rheumatoid Arthritis Subjects
Kimberly Robasky¹, Jatinder Kaur², Jennifer Sims¹, Melissa Howard¹, Eric Earley¹ and Eric Lai², ¹EA|Quintiles, Durham, NC, ²Takeda Pharmaceuticals International, Inc., Deerfield, IL
Background/Purpose: Human leukocyte antigen (HLA) genes code for proteins that allow the immune system to distinguish self from foreign cells. These genes have important indications…
Abstract Number: 2617 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis
Olga S. Zhukov¹, Jonnielyn G. Rivera¹, Rania W. Abolhosn¹, Robert J. Lagier², Charles M. Rowland³, Joanna M. Popov¹, Kaleb Michaud⁴ and Stanley J. Naides¹, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ³Research Support, Quest Diagnostics Alameda, Alameda, CA, ⁴Rheumatology & Immunology, University of Nebraska Medical Center and National Data Bank, Omaha, NE
Background/Purpose: Tissue distribution of the chaperonin 14-3-3η (eta) is limited to synovial tissue and brain. Synovium releases proinflammatory 14-3-3η into synovial fluid and serum in…
Abstract Number: 292 • 2015 ACR/ARHP Annual Meeting
Neoepitope Biomarkers As Biomarkers of Polymyositis and Dermatomyositis and Functional Status
Anders Nedergaard¹, Kim Henriksen², Morten Asser Karsdal³, Wendy White⁴ and Xiang Guo⁴, ¹Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, Copenhagen NW, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are inflammatory conditions characterized by persistent inflammation of muscle tissue (and for DM also skin). Myositis has been shown…
Abstract Number: 2653 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis
Uta Kiltz¹, Christine von Zabern¹, Xenofon Baraliakos¹, Frank Heldmann¹, Bernhard Mintrop¹, Michael Sarholz¹, Martin van Werde¹, Claudia Klink², Dietmar Krause², Friedrich Dybowski³, Ludwig Kalthoff³, Liane Hein³ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Private rheumatology office, Gladbeck, Germany, ³Private rheumatology office, Herne, Germany
Background/Purpose: In patients with tender and swollen finger joints, the differential diagnosis between rheumatoid arthritis (RA) and osteoarthritis (OA) of the hands can be initially…
Abstract Number: 405 • 2015 ACR/ARHP Annual Meeting
Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
Thaschawee Arkachaisri^1,2, Justin Hung Tiong Tan¹, Manasita Tanya¹, Sook Fun Hoh³, Lena Das⁴ and Jing Yao Leong^5,6, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore, ³Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁵Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ⁶SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore
Background/Purpose: Anti-C1q antibodies (AC1q) were shown to strongly correlate with the occurrence and activity of lupus nephritis in adult SLE. Data of the antibodies in…
Abstract Number: 2695 • 2015 ACR/ARHP Annual Meeting
Th17 Cell Related Cytokines and Microarray Expression Profiles in Patients with Early Rheumatoid Arthritis
Youngkyun Kim¹, Kijun Lee², Hae-Rim Kim³, Sang Heon Lee⁴, Ji Hyeon Ju⁵ and HO-YOUN KIM⁶, ¹1Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, ²The Catholic University of Korea, Seoul, South Korea, ³Konkuk University Medical Center, Seoul, South Korea, ⁴Konkuk University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Konkuk university hospital, Seoul, South Korea
Background/Purpose: The purpose of this study is to explore new biomarkers for early diagnosis of rheumatoid arthritis (RA). For better discrimination power, we especially investigated…
Abstract Number: 765 • 2015 ACR/ARHP Annual Meeting
Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway
Chaim Putterman¹, Jill P. Buyon², Richard Furie³, Rosalind Ramsey-Goldman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁷, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²NYU School of Medicine, New York, NY, ³NSLIJHS, Lake Success, NM, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁷Research and Development, Exagen Diagnostics, Vista, CA, ⁸Exagen Diagnostics, Vista, CA
Background/Purpose : There is a need to identify biomarkers that track disease response in systemic lupus erythematosus (SLE). The value of various biomarkers in monitoring…
Abstract Number: 2917 • 2015 ACR/ARHP Annual Meeting
Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?
Ryota Sakai¹, Akiko Shibata¹, Kentaro Chino¹, Jun Kikuchi², Tsuneo Kondo¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano¹, ¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Using light microscopy (LM) or immunofluorescence (IF), combined proliferative and membranous lupus nephritis (LN) is defined as an active proliferative class III/IV lesion and…
Abstract Number: 767 • 2015 ACR/ARHP Annual Meeting
Estimating the Pre-Test Probability of Systemic Lupus Erythematosus By Utilizing Anti-Double Stranded DNA and Cell Bound Complement Activation Products Testing from Rheumatology Based Practices in the United States
Stuart L. Silverman¹, Derren Barken², John Conklin³, Claudia Ibarra⁴ and Thierry Dervieux⁵, ¹OMC Clinical Research Center, Beverly Hills, CA, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose : Clinicians are aware that the interpretation of any clinical diagnostic test and post-test probability of disease is highly influenced by pre-test probability or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.